Nematicides Market worth $5.60 billion by 2031- Exclusive Report by MarketsandMarkets™

MarketsandMarkets estimates the global nematicides market at $3.36B in 2026, rising to $5.60B by 2031 (10.7% CAGR). Growth is attributed to rising plant-parasitic nematode damage, shift toward bio-based solutions amid stricter chemical fumigant regulation, and adoption of integrated pest management and precision/seed-applied technologies. The biologicals segment is projected to grow fastest (15.7% CAGR), while liquid formulations are forecast to hold a 64.1% share in 2026; Europe is expected to lead with a 12.8% CAGR. The article also highlights increased investment and deal activity to expand biological crop-protection capabilities.

Analysis

This reads less like a near-term earnings catalyst and more like an evidence trail for where crop-protection mix is heading: toward higher-margin, lower-residue biological and seed-applied products, with the main economic value accruing to companies that own distribution, trialing data, and bundling power rather than to whoever has the most branded chemistry. The second-order winner is likely the platform player that can cross-sell nematode control into broader seed-treatment packages; that favors diversified crop-science franchises over niche formulators, especially if growers demand one-stop solutions to satisfy residue and regulatory constraints.

The market should also be careful not to extrapolate TAM growth into immediate EPS upside. Nematode pressure is highly crop- and region-specific, so monetization will be lumpy and dependent on planting mix, weather, and adoption cycles; the P&L impact is more likely a 1-3 year revenue share shift than a 1-quarter step-up. If biologicals continue taking share, smaller chemical-heavy suppliers face margin pressure from channel substitution and pricing erosion, while larger players can defend through bundled offerings and M&A.

Contrarian view: the consensus may be overestimating how quickly biology displaces chemistry. Chemical products still appear to be the commercial default where efficacy is most visible, and biological uptake usually needs multiple seasons of proof before it moves from pilot to acreage scale. That means the real tradable catalyst is not the market-size headline itself but evidence of procurement reallocation in seed treatments and soil applications; absent that, the move is probably better expressed as a watchlist than a high-conviction macro trade.

Key Decisions for Investors

• Long CTVA vs. short FMC over 3-6 months: CTVA has better exposure to seed-treatment bundling and biological adjacency; FMC is more likely to see this as a peripheral mix item. Target a modest relative-performance spread, cut if FMC shows evidence of stronger crop-protection mix than expected.
• Add BASFY and BAYRY only on weakness, not on the headline: both are better viewed as strategic beneficiaries of portfolio breadth and Europe regulatory tightening, but the revenue lift is likely deferred. Use them as 12-18 month compounders rather than immediate event trades.
• Do not chase AVD on the report alone; instead, set a watch for channel checks on nematicide demand and balance-sheet commentary. If AVD can show share gains in soil-applied products without margin dilution, it becomes a small-cap rerating candidate; absent that, risk/reward is limited.
• Alert for evidence of M&A or licensing in agricultural biologicals over the next 1-2 quarters. If a large-cap crop-science name acquires a bionematicide platform, that is the cleaner tradeable signal than the market-size forecast itself.
• Falsifier: if 1H-2027 commentary from CTVA/BAYRY/BASFY shows no uptick in seed-treatment or soil-applied biological adoption, treat the theme as narrative-heavy and fade any multiple expansion.